1. Home
  2. AMC vs DRUG Comparison

AMC vs DRUG Comparison

Compare AMC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Entertainment Holdings Inc.

AMC

AMC Entertainment Holdings Inc.

HOLD

Current Price

$1.61

Market Cap

786.8M

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$88.83

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMC
DRUG
Founded
1920
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
786.8M
707.1M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
AMC
DRUG
Price
$1.61
$88.83
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$2.03
$129.25
AVG Volume (30 Days)
33.5M
151.6K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,848,900,000.00
N/A
Revenue This Year
$11.41
N/A
Revenue Next Year
$5.18
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.57
N/A
52 Week Low
$0.93
$23.18
52 Week High
$4.08
$123.75

Technical Indicators

Market Signals
Indicator
AMC
DRUG
Relative Strength Index (RSI) 60.93 59.33
Support Level $1.44 $72.06
Resistance Level $1.79 $91.69
Average True Range (ATR) 0.15 4.13
MACD 0.00 0.25
Stochastic Oscillator 49.23 69.87

Price Performance

Historical Comparison
AMC
DRUG

About AMC AMC Entertainment Holdings Inc.

AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: